134 related articles for article (PubMed ID: 38056112)
1. The use of axillary ultrasound (AUS) to assess the nodal status after neoadjuvant chemotherapy (NACT) in primary breast cancer patients.
Leinert E; Lukac S; Schwentner L; Coenen A; Fink V; Veselinovic K; Dayan D; Janni W; Friedl TWP
Surg Oncol; 2024 Feb; 52():102016. PubMed ID: 38056112
[TBL] [Abstract][Full Text] [Related]
2. Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
Skarping I; Förnvik D; Zackrisson S; Borgquist S; Rydén L
Breast Cancer Res Treat; 2021 Aug; 189(1):131-144. PubMed ID: 34120224
[TBL] [Abstract][Full Text] [Related]
3. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT).
Peppe A; Wilson R; Pope R; Downey K; Rusby J
Breast; 2017 Oct; 35():104-108. PubMed ID: 28704697
[TBL] [Abstract][Full Text] [Related]
4. Axillary ultrasonography combined with pre-operative wire localisation of clipped node in nodal restaging after neoadjuvant chemotherapy in node positive breast cancer patients: a pilot study.
Pulappadi VP; Paul S; Hari S; Dhamija E; Manchanda S; Kataria K; Mathur S; Mani K; Gogia A; Deo S
Br J Radiol; 2021 Nov; 94(1127):20210788. PubMed ID: 34491822
[TBL] [Abstract][Full Text] [Related]
5. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
[TBL] [Abstract][Full Text] [Related]
6. Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
Boughey JC; Ballman KV; Hunt KK; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Le-Petross HT
J Clin Oncol; 2015 Oct; 33(30):3386-93. PubMed ID: 25646192
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic contribution of magnetic resonance imaging in the detection of axillary metastasis after neoadjuvant chemotherapy.
İriağaç Y; Karaboyun K; Çavdar E; Avci O; Kurtoğlu Özçağlayan Tİ; Öznur M; Ozkan Gurdal S; Şeber ES
Neoplasma; 2022 May; 69(3):741-746. PubMed ID: 35471979
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
[TBL] [Abstract][Full Text] [Related]
9. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Garcia-Tejedor A; Fernandez-Gonzalez S; Ortega R; Gil-Gil M; Perez-Montero H; Fernandez-Montolí E; Stradella A; Recalde S; Soler T; Petit A; Bajen MT; Benitez A; Guma A; Campos M; Pla MJ; Martinez E; Laplana M; Pernas S; Perez-Sildekova D; Catala I; Ponce J; Falo C
Breast Cancer Res Treat; 2021 Feb; 185(3):657-666. PubMed ID: 33068198
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis.
Keelan S; Heeney A; Downey E; Hegarty A; Roche T; Power C; Mhuircheartaigh NN; Duke D; Kerr J; Hambly N; Hill A
Breast Cancer Res Treat; 2021 Jun; 187(2):303-310. PubMed ID: 33837870
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in patients with breast cancer: Does response in the breast predict axillary node response?
Morgan C; Stringfellow TD; Rolph R; Kovacs T; Kothari A; Pinder SE; Hamed H; Sever AR
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):522-526. PubMed ID: 31740186
[TBL] [Abstract][Full Text] [Related]
13. Patients with initial nodal involvement due to breast cancer who have received neoadjuvant chemotherapy: Combined sentinel node-radioguided surgery of the pathological node.
Fuertes Manuel J; Kohan S; Jordà Solé M; Mateu Hidalgo I; Miralles Curto M; Aguiló Sagristà O; Aguilar Alomá E; Peña González K; Lafuerza Torres A; Melé Olivé M; Repkova J; Montero Jaime MJ; Gumà Padró J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(5):284-291. PubMed ID: 35597764
[TBL] [Abstract][Full Text] [Related]
14. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.
Banys-Paluchowski M; Gruber IV; Hartkopf A; Paluchowski P; Krawczyk N; Marx M; Brucker S; Hahn M
Arch Gynecol Obstet; 2020 Feb; 301(2):341-353. PubMed ID: 31897672
[TBL] [Abstract][Full Text] [Related]
15. Routine Axillary Ultrasound for Patients with T1-T2 Breast Cancer Does Not Increase the Rate of Axillary Lymph Node Dissection Based on Predictive Modeling.
Wellington J; Sanders T; Mylander C; Alden A; Harris C; Buras R; Tafra L; Liang W; Stelle L; Rosman M; Jackson RS
Ann Surg Oncol; 2018 Aug; 25(8):2271-2278. PubMed ID: 29868976
[TBL] [Abstract][Full Text] [Related]
16. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
17. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of magnetic resonance imaging to evaluate axillary lymph node status in breast cancer patients receiving neoadjuvant chemotherapy.
Bansal GJ; Jaipal A; Wu GKC; Syed A
Br J Radiol; 2023 Mar; 96(1143):20220904. PubMed ID: 36607272
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
[TBL] [Abstract][Full Text] [Related]
20. Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.
Chen M; Li S; Huang M; Guo J; Huang X; Guo W; Chen L; Lin Y; Jacobs L; Wang C; Fu F
Breast Cancer Res Treat; 2022 Nov; 196(2):267-277. PubMed ID: 36100784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
